1558 — Yichang Hec Changjiang Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapSuper Stock

Market Cap
HK$11.44bn
Enterprise Value
HK$12.43bn
Revenue
CNY6.29bn

Annual income statement for Yichang Hec Changjiang Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	6,224	2,348	914	3,745	6,295
Cost of Revenue
Gross Profit	5,302	1,997	484	2,846	4,986
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	3,750	1,093	1,337	3,424	3,940
Operating Profit	2,474	1,255	-423	321	2,354
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	2,269	1,010	-667	39.4	2,127
Provision for Income Taxes
Net Income After Taxes	1,907	837	-588	49.2	1,856
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,919	839	-588	76.6	1,993
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	2,087	590	-588	76.6	1,993
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.05	0.538	-0.635	0.301	2.75
Dividends per Share